# Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)

> **NCT01932762** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 98 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Grazoprevir
- **DRUG:** Elbasvir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01932762
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-01
- **Primary completion:** 2014-12-04
- **Final completion:** 2014-12-04
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2021-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01932762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01932762, "Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01932762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*